Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race

January 26, 2015 6:16 AM

3 0

Regeneron (REGN:US) Pharmaceuticals Inc. and Sanofi (SAN) may get a head start on their biggest competitor in bringing a new class of cholesterol drugs to the U.S. market.

The U.S. Food and Drug Administration has until July 24 to make a decision on the companies’ application to market their jointly developed drug alirocumab, Regeneron and Sanofi said in a statement.

Read more

To category page